Key Takeaways
- The FDA’s ODAC advisory committee rejected AstraZeneca’s camizestrant with a 6-3 vote against approval
- Separately, advisors endorsed Truqap for prostate cancer treatment with a 7-1 favorable vote
- Shares of AZN declined 1.13% in premarket sessions to $185.25
- Analysts at Morgan Stanley highlighted potential “regulatory overhang” concerns after the camizestrant decision
- The pharmaceutical company expressed disappointment but maintains confidence in camizestrant’s clinical data
AstraZeneca received contrasting outcomes from FDA advisory panels on Thursday, as regulators evaluated two separate oncology treatments with divergent results.
Shares traded lower by 1.13% during premarket hours on Friday, reaching $185.25. The stock has declined approximately 6.9% over the trailing 30-day period, underperforming the S&P 500’s 9.9% gain during the same timeframe.
The Oncologic Drugs Advisory Committee (ODAC) at the FDA examined two distinct cancer therapies from AstraZeneca during Thursday’s proceedings — delivering markedly different recommendations for each candidate.
The disappointing news centered on camizestrant, where panelists voted 6-3 against recommending approval. The oral medication targets HR-positive, HER2-negative advanced breast cancer patients carrying ESR1 mutations and was positioned as a first-line therapeutic option.
Advisory members concluded that camizestrant failed to demonstrate sufficient clinical benefit for patients whose cancer had not yet advanced on existing treatment regimens.
According to findings from the SERENA-6 clinical trial, camizestrant delivered a 56% reduction in either disease advancement or mortality. Trial participants receiving the experimental drug experienced a median progression-free survival of 16 months, substantially longer than the 9.2-month median observed with current standard treatments.
However, committee members expressed reservations regarding the completeness of crucial secondary endpoints, particularly overall survival metrics and time until second progression, which were assessed during an interim analysis phase.
A subsequent pre-scheduled analysis demonstrated statistically significant PFS2 advantages — extending to 25.7 months versus 19.1 months — while overall survival data continued showing favorable trends for camizestrant-treated patients.
AstraZeneca expressed disappointment with the advisory outcome but reaffirmed its confidence in the clinical evidence supporting the drug’s therapeutic value for patients.
Wall Street Analysts Highlight Regulatory Uncertainty
Analysts from Morgan Stanley, under the leadership of Sarita Kapila, characterized the unfavorable vote as creating “regulatory overhang and a dent to investor sentiment.”
The research team acknowledged that FDA approval remains within the realm of possibility, but emphasized that the 6-3 vote diminishes probability for the SERENA-6 indication. While the FDA maintains independence from advisory committee recommendations, the agency historically aligns with panel guidance in most cases. A definitive regulatory determination is anticipated in the coming period.
Prostate Cancer Drug Truqap Receives Strong Advisory Support
The day brought more encouraging developments on another front. ODAC panelists voted 7-1 to recommend Truqap (capivasertib) for approval, when administered alongside abiraterone and androgen deprivation therapy for treating PTEN-deficient metastatic hormone-sensitive prostate cancer patients.
This positive recommendation stems from Phase 3 CAPItello-281 trial outcomes, which demonstrated a 19% risk reduction for disease progression or patient mortality.
Patients in the Truqap treatment arm achieved median radiographic progression-free survival of 33.2 months, surpassing the 25.7-month median recorded in the control cohort.
Additional secondary measures reinforced the combination therapy’s advantages, including extended time before progression to castration-resistant disease and enhanced PSA marker responses.
The safety characteristics aligned with established knowledge about these therapeutic agents, although Grade 3 or more severe adverse reactions occurred with greater frequency in patients receiving Truqap. Overall survival information continues to develop but shows favorable directional trends for the combination approach.
Year-to-date, AZN shares remain essentially unchanged, while the broader S&P 500 index has appreciated 4.8% during the identical timeframe.
